Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cerilliant
Daiichi Sankyo
Harvard Business School
QuintilesIMS
Mallinckrodt
Express Scripts
Baxter
Healthtrust
Boehringer Ingelheim
US Army

Generated: January 16, 2018

DrugPatentWatch Database Preview

Raloxifene hydrochloride - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for raloxifene hydrochloride and what is the scope of raloxifene hydrochloride freedom to operate?

Raloxifene hydrochloride
is the generic ingredient in two branded drugs marketed by Lilly, Amneal Pharms, Aurobindo Pharma Ltd, Glenmark Pharms Ltd, Invagen Pharms, Sciegen Pharms Inc, Teva Pharms Usa, and Watson Labs Inc, and is included in eight NDAs. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Raloxifene hydrochloride has forty-five patent family members in thirty-three countries and two supplementary protection certificates in two countries.

There are sixteen drug master file entries for raloxifene hydrochloride. Twenty-two suppliers are listed for this compound.
Summary for raloxifene hydrochloride
Pharmacology for raloxifene hydrochloride
Medical Subject Heading (MeSH) Categories for raloxifene hydrochloride

US Patents and Regulatory Information for raloxifene hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glenmark Pharms Ltd RALOXIFENE HYDROCHLORIDE raloxifene hydrochloride TABLET;ORAL 204491-001 Mar 22, 2016 AB RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Sciegen Pharms Inc RALOXIFENE HYDROCHLORIDE raloxifene hydrochloride TABLET;ORAL 206384-001 Oct 12, 2016 AB RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Lilly EVISTA raloxifene hydrochloride TABLET;ORAL 020815-001 Dec 9, 1997 AB RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Watson Labs Inc RALOXIFENE HYDROCHLORIDE raloxifene hydrochloride TABLET;ORAL 200825-001 Jan 21, 2015 AB RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Amneal Pharms RALOXIFENE HYDROCHLORIDE raloxifene hydrochloride TABLET;ORAL 208206-001 Apr 8, 2016 AB RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Lilly EVISTA raloxifene hydrochloride TABLET;ORAL 020815-001 Dec 9, 1997 AB RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Aurobindo Pharma Ltd RALOXIFENE HYDROCHLORIDE raloxifene hydrochloride TABLET;ORAL 204310-001 Aug 28, 2015 AB RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Lilly EVISTA raloxifene hydrochloride TABLET;ORAL 020815-001 Dec 9, 1997 AB RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Invagen Pharms RALOXIFENE HYDROCHLORIDE raloxifene hydrochloride TABLET;ORAL 090842-001 Sep 24, 2014 AB RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Lilly EVISTA raloxifene hydrochloride TABLET;ORAL 020815-001 Dec 9, 1997 AB RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for raloxifene hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Lilly EVISTA raloxifene hydrochloride TABLET;ORAL 020815-001 Dec 9, 1997 ➤ Subscribe ➤ Subscribe
Lilly EVISTA raloxifene hydrochloride TABLET;ORAL 020815-001 Dec 9, 1997 ➤ Subscribe ➤ Subscribe
Lilly EVISTA raloxifene hydrochloride TABLET;ORAL 020815-001 Dec 9, 1997 ➤ Subscribe ➤ Subscribe
Lilly EVISTA raloxifene hydrochloride TABLET;ORAL 020815-001 Dec 9, 1997 ➤ Subscribe ➤ Subscribe
Lilly EVISTA raloxifene hydrochloride TABLET;ORAL 020815-001 Dec 9, 1997 ➤ Subscribe ➤ Subscribe
Lilly EVISTA raloxifene hydrochloride TABLET;ORAL 020815-001 Dec 9, 1997 ➤ Subscribe ➤ Subscribe
Lilly EVISTA raloxifene hydrochloride TABLET;ORAL 020815-001 Dec 9, 1997 ➤ Subscribe ➤ Subscribe
Lilly EVISTA raloxifene hydrochloride TABLET;ORAL 020815-001 Dec 9, 1997 ➤ Subscribe ➤ Subscribe
Lilly EVISTA raloxifene hydrochloride TABLET;ORAL 020815-001 Dec 9, 1997 ➤ Subscribe ➤ Subscribe
Lilly EVISTA raloxifene hydrochloride TABLET;ORAL 020815-001 Dec 9, 1997 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for raloxifene hydrochloride

Supplementary Protection Certificates for raloxifene hydrochloride

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB98/048 United Kingdom ➤ Subscribe PRODUCT NAME: RALOXIFENE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: UK EU/1/98/073/001 19980805; UK EU/1/98/073/002 19980805; UK EU/1/98/073/003 19980805; UK EU/1/98/073/004 19980805; UK EU/1/98/074/001 19980805; UK EU/1/98/074/002 19980805; UK EU/1/98/074/003 19980805; UK EU/1/98/074/004 19980805
0044 Netherlands ➤ Subscribe PRODUCT NAME: RALOXIFENE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAAR DBAAR ZOUT, IN HET BIJZONDER HET HYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/98/073/001 - EU/1/98/073/004, EU/1/98/074/001 - EU/1/98/074/004 19980805 EU/1/98/073/001
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Fish and Richardson
Cipla
QuintilesIMS
Mallinckrodt
Teva
US Department of Justice
Citi
McKinsey
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot